SA Insights: From Lab to Launch: How Seonix Bio is commercialising genomics for Glaucoma Risk Assessment.

Join us for the next MTPConnect SA Insights event, where we’ll spotlight Seonix Bio, an Adelaide-based company pioneering genetic testing for glaucoma risk assessment.

Seonix Bio’s flagship product, SightScore, is a groundbreaking clinical tool that analyses millions of genetic variants from a simple saliva sample to generate a personalised   risk score for primary open-angle glaucoma. This enables earlier detection, personalised treatment plans, and more effective monitoring strategies for patients at risk .

Learn about the commercialisation and translational journey of this spin-out company who are distributing to global markets.

Speakers:

• Professor Jamie Craig | Internationally recognised ophthalmic geneticist, co-founder of Seonix Bio, and South Australian Scientist of the Year 2024
• Nick Haan | CEO,  Seonix Bio

They will share insights into the development of SightScore and its potential to transform glaucoma care through genetic risk prediction.

Don’t miss this opportunity to connect with innovators shaping the future of eye health.

Who should attend:

• Researchers and scientists
• Entrepreneurs and business owners
• Policy makers and regulators
• Healthcare professionals
• Investors and industry partners